Skip to main content
Fig. 5 | Breast Cancer Research

Fig. 5

From: Neutrophils drive accelerated tumor progression in the collagen-dense mammary tumor microenvironment

Fig. 5

Neutrophil depletion with anti-Ly6G antibody reduces collagen-dense tumor formation as measured by 18FDG-PET glucose uptake. a Experimental time line showing timing of injections of 5.5 μg/g of control IgG (2A3) or Ly6G (1A8) into the peritoneal cavity of wild-type (WT) tumor mice and tumor mice expressing the polyoma virus antigen and heterozygote for the col1a1 mutation (COL) mice (n = 5–6 in each group) at 9 weeks of age for 24 days. Yellow arrows indicate day of 2’-deoxy-2’-[18F]fluoro-D-glucose (18FDG) hybrid positron emission tomography (PET)-computed tomography (CT) imaging. Black arrows indicate day of treatment. Red arrows indicate day of blood collection. Green arrow indicates day of tissue collection (tumors, spleens, and lungs). b Detection of mammary tumors by 18FDG-PET/CT. Coronal sections of co-registered 18FDG-PET and CT images of WT and COL tumor mice before treatment at 9 weeks of age (Day −1) and after treatment at 12 weeks of age (Day 21). Regions of interest are drawn and colored at the mouse mammary glands with visible tumors. Physiologic tracer uptake in heart (H), kidneys (K), and bladder (B) is marked. Total number of tumors in c WT mice and e COL mice as determined by 18FDG-PET at day −1 (D –1) and day 21 (D 21). Sum of the mass (mm3) of all tumors per WT (d) and COL mouse (f) at day −1 and day 21 (n = 5–6; each data point equals one mouse). Note that there is a trend toward decreased tumor burden in anti-Ly6G-treated COL tumors (p = 0.24). g Mean glucose uptake (percent injection dose per gram (%ID/g) in WT and COL (i) tumors at day −1 and day 21. h Maximum glucose uptake (%ID/g)) in WT and j COL tumors at day −1 and day 21 (n = 32–46; each data point equals one tumor)

Back to article page